前立腺の健康の世界市場

前立腺の健康の世界市場は2030年までに512億米ドルに達する見込み

2024年に338億米ドルと推定される前立腺の健康の世界市場は、2024年から2030年にかけてCAGR 7.2％で成長し、2030年には512億米ドルに達すると予測されます。本レポートで分析したセグメントの1つである前立腺炎疾患は、CAGR 5.7%を記録し、分析期間終了時には274億米ドルに達すると予測されます。良性前立腺肥大症型セグメントの成長率は、分析期間でCAGR 9.4％と推定されます。

米国市場は92億米ドルと推定、中国はCAGR11.0％で成長予測

米国の前立腺の健康市場は、2024年に92億米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに106億米ドルの市場規模に達すると予測され、分析期間2024-2030年のCAGRは11.0%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ3.7%と6.8%と予測されています。欧州では、ドイツがCAGR 4.7%で成長すると予測されています。

世界の「前立腺の健康」市場- なぜプロアクティブケアが世界のメンズヘルスにとって必須となりつつあるのか？

高齢化が前立腺の健康の必要性を高めている？

前立腺の健康は、男性人口の急速な高齢化と泌尿器疾患に対する意識の高まりにより、世界のヘルスケアシステムの中心的な関心事となりつつあります。前立腺肥大症（BPH）、前立腺炎、前立腺がんなどの前立腺関連疾患は、50歳以上の男性の間でますます流行しており、予防、診断、治療ソリューションに対する着実な需要を生み出しています。公衆衛生キャンペーンやスクリーニング・プロトコルの強化が早期発見につながり、予後の改善や治療期間の拡大に寄与しています。さらに、肥満、喫煙、座りっぱなしの習慣など、生活習慣に関連する危険因子が、若年層でも前立腺疾患の発生率を悪化させています。PSA検査、MRI、経直腸超音波検査などの診断ツールの拡充により、前立腺の健康によるモニタリングはより身近で正確なものとなっています。特に北米、欧州、アジアの一部では、政府や医療機関が前立腺ケアを男性の定期健康診断に組み込んでおり、臨床的介入に対する認識と需要がさらに高まっています。

診断と治療における革新は臨床成果を高めているか？

前立腺の健康市場は、診断・治療技術の進歩から大きな恩恵を受けています。レーザー治療、TURP（経尿道的前立腺切除術）、最新のロボット支援手術などの低侵襲手術技術は、回復時間を短縮し、患者の生活の質を向上させています。薬理学的な革新も重要な役割を果たしています。新しい世代のα遮断薬、5α還元酵素阻害薬、ホルモン療法は、より少ない副作用でより的を絞った症状管理を提供しています。画像診断では、マルチパラメトリックMRIやバイオマーカーに基づく検査により、良性疾患と悪性腫瘍の鑑別をより早く、より正確に行えるようになり、精度が高まっています。さらに、免疫療法や放射性医薬品の研究は、進行期の前立腺がんの治療に有望視されています。遠隔泌尿器科プラットフォームやモバイルヘルスアプリなどのデジタルヘルスツールは、患者のコンプライアンス、症状追跡、バーチャルコンサルテーションをサポートしています。診断と治療がより統合されるにつれて、全体的なケア経路が出現し、臨床ワークフローと患者の転帰が改善されつつあります。

男性の健康意識と消費行動が需要を牽引？

男性の健康に対する取り組み方における社会的なシフトは、前立腺の健康の状況を一変させつつあります。従来はスティグマ（烙印）や軽視のために過小診断されてきた前立腺疾患は、著名人、医学会、デジタル・インフルエンサーによる擁護のおかげで、現在では注目度が高まっています。若い世代は予防医療に積極的で、定期検診や遺伝子スクリーニングに参加しています。消費者直販の健康プラットフォームや家庭用検査キットは、男性に健康管理の自主性を与え、薬局やプライマリケアクリニックは前立腺に特化したサービスをより利用しやすくしています。性的な健康や生活の質を重視する傾向が強まっていることも、BPHや勃起不全のような、しばしば前立腺の健康と相互に関連する疾患の早期治療を求める患者を後押ししています。男性は、失禁やがんなど、前立腺疾患の長期的な影響について知識を深めているため、プレミアム診断、セカンドオピニオン、継続的なケアレジメンに投資する意欲が高まっています。このような行動動向により、市場は消極的な治療から、より予防的で個別化された患者中心のモデルへと徐々にシフトしつつあります。

前立腺の健康市場の成長はいくつかの要因によってもたらされる...

前立腺の健康市場の成長は、人口動向、進化する診断法、消費者行動の変化に関連するいくつかの要因によって牽引されています。低侵襲手技、バイオマーカー検査、画像診断モダリティの技術的進歩により、より早期の診断とオーダーメイドの介入が可能になりつつあります。最終用途の観点からは、泌尿器科クリニック、専門病院、外来センターにおける患者数の増加が、特に高齢化経済において、包括的なスクリーニングと治療サービスの需要を押し上げています。消費者の嗜好も進化しており、遠隔医療、個別化医療、在宅検査ソリューションの受け入れ拡大が、医療の提供・消費方法に影響を与えています。特に新興市場におけるヘルスケア・インフラの拡充は、前立腺の健康サービスへの幅広いアクセスを可能にしています。さらに、前立腺関連疾患に対する医薬品パイプラインは強固で、新規ホルモン療法や併用レジメンに焦点を当てた臨床試験が数多く実施されています。医療技術革新、患者意識、制度的支援が交差することで、前立腺の健康市場が世界的に持続的に成長するための肥沃な環境が整いつつあります。

セグメント

疾患タイプ（前立腺炎疾患タイプ、前立腺肥大症疾患タイプ、前立腺がん疾患タイプ）、治療（化学療法治療、ホルモン療法治療、免疫療法治療）、投与経路（経口経路、非経口経路）、流通チャネル（病院薬局流通チャネル、小売薬局流通チャネル、オンライン薬局流通チャネル）

調査対象企業の例（合計 37注目）

• Abbott Laboratories
• Amgen Inc.
• Astellas Pharma Inc.
• AstraZeneca PLC
• Bayer AG
• Bristol-Myers Squibb Company
• Clovis Oncology, Inc.
• Eli Lilly and Company
• Endo Pharmaceuticals Inc.
• Ferring Pharmaceuticals Inc.
• GlaxoSmithKline plc
• Johnson & Johnson
• Merck & Co., Inc.
• Novartis AG
• Pfizer Inc.
• ProArc Medical Ltd.
• Quibim
• Sanofi
• Siemens Healthineers AG
• Veru Inc.

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、人為的な売上原価の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

Global Industry Analystsは、世界の主要なチーフ・エコノミスト（1万4,949人）、シンクタンク（62団体）、貿易・産業団体（171団体）の専門家の意見に熱心に従いながら、エコシステムへの影響を評価し、新たな市場の現実に対処しています。あらゆる主要国の専門家やエコノミストが、関税とそれが自国に与える影響についての意見を追跡調査しています。

Global Industry Analystsは、この混乱が今後2-3ヶ月で収束し、新しい世界秩序がより明確に確立されると予想しています。Global Industry Analystsは、これらの開発をリアルタイムで追跡しています。

2025年4月：交渉フェーズ

4月のリリースでは、世界市場全体に対する関税の影響を取り上げ、地域別の市場調整について紹介します。当社の予測は、過去のデータと進化する市場影響要因に基づいています。

2025年7月：最終関税リセット

お客様には、各国間で最終リセットが発表された後、7月に無料アップデート版をお届けします。最終アップデート版には、明確に定義された関税影響分析が組み込まれています。

相互および二国間貿易と関税の影響分析：

アメリカ <>中国<>メキシコ <>カナダ <>EU <>日本<>インド <>その他176カ国

業界をリードするエコノミスト：Global Industry Analystsの知識ベースは、国家、シンクタンク、貿易・産業団体、大企業、そして世界の計量経済状況におけるこの前例のないパラダイムシフトの影響を共有する領域の専門家など、最も影響力のあるチーフエコノミストの厳選されたグループを含む1万4,949人のエコノミストを追跡しています。当社の16,491を超えるレポートのほとんどは、マイルストーンに基づくこの2段階のリリーススケジュールを取り入れています。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

• 市場概要
• 主要企業
• 市場動向と促進要因
• 世界市場の見通し

第3章 市場分析

• 米国
• カナダ
• 日本
• 中国
• 欧州
• フランス
• ドイツ
• イタリア
• 英国
• スペイン
• ロシア
• その他欧州
• アジア太平洋
• オーストラリア
• インド
• 韓国
• その他アジア太平洋地域
• ラテンアメリカ
• アルゼンチン
• ブラジル
• メキシコ
• その他ラテンアメリカ
• 中東
• イラン
• イスラエル
• サウジアラビア
• アラブ首長国連邦
• その他中東
• アフリカ

第4章 競合

Global Prostate Health Market to Reach US$51.2 Billion by 2030

The global market for Prostate Health estimated at US$33.8 Billion in the year 2024, is expected to reach US$51.2 Billion by 2030, growing at a CAGR of 7.2% over the analysis period 2024-2030. Prostatitis Disease, one of the segments analyzed in the report, is expected to record a 5.7% CAGR and reach US$27.4 Billion by the end of the analysis period. Growth in the Benign Prostatic Hyperplasia Type segment is estimated at 9.4% CAGR over the analysis period.

The U.S. Market is Estimated at US$9.2 Billion While China is Forecast to Grow at 11.0% CAGR

The Prostate Health market in the U.S. is estimated at US$9.2 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$10.6 Billion by the year 2030 trailing a CAGR of 11.0% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 3.7% and 6.8% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 4.7% CAGR.

Global "Prostate Health" Market - Why Is Proactive Care Becoming a Global Men’s Health Imperative?

Is the Aging Population Raising the Urgency Around Prostate Health?

Prostate health is becoming a central concern in global healthcare systems, largely due to the rapid aging of the male population and increased awareness around urological conditions. Prostate-related disorders such as benign prostatic hyperplasia (BPH), prostatitis, and prostate cancer are increasingly prevalent among men aged 50 and above, creating steady demand for preventive, diagnostic, and therapeutic solutions. Public health campaigns and enhanced screening protocols have led to early detection, contributing to better prognosis and a wider treatment window. Additionally, lifestyle-related risk factors-such as obesity, smoking, and sedentary habits-are exacerbating the incidence of prostate issues, even in younger age groups. The expansion of diagnostic tools like PSA testing, MRI, and transrectal ultrasound is making prostate health monitoring more accessible and precise. Governments and health organizations are integrating prostate care into regular male health checkups, particularly in North America, Europe, and parts of Asia, further boosting awareness and demand for clinical interventions.

Are Innovations in Diagnosis and Treatment Enhancing Clinical Outcomes?

The prostate health market is benefiting significantly from advancements in diagnostic and therapeutic technologies. Minimally invasive surgical techniques, such as laser therapy, TURP (transurethral resection of the prostate), and newer robotic-assisted procedures, are reducing recovery time and improving quality of life for patients. Pharmacological innovation is also playing a key role; newer generations of alpha-blockers, 5-alpha reductase inhibitors, and hormone therapies are offering more targeted symptom management with fewer side effects. Diagnostic imaging is becoming more precise with multiparametric MRI and biomarker-based tests allowing earlier and more accurate differentiation between benign conditions and malignancies. Furthermore, research into immunotherapy and radiopharmaceuticals is showing promise in treating advanced-stage prostate cancer. Digital health tools, such as tele-urology platforms and mobile health apps, are supporting patient compliance, symptom tracking, and virtual consultations. As diagnostics and therapeutics become more integrated, holistic care pathways are emerging, improving clinical workflows and patient outcomes.

Is Male Health Awareness and Consumer Behavior Driving Demand?

Societal shifts in how men approach their health are transforming the prostate health landscape. Traditionally underdiagnosed due to stigma and neglect, prostate conditions are now receiving increased attention thanks to advocacy from celebrities, medical societies, and digital influencers. Younger generations are more proactive about preventive care, participating in regular checkups and genetic screenings. Direct-to-consumer health platforms and home testing kits are giving men more autonomy in managing their health, while pharmacies and primary care clinics offer greater accessibility to prostate-specific services. The growing emphasis on sexual wellness and quality of life is also pushing patients to seek early treatment for conditions like BPH and erectile dysfunction, which are often interlinked with prostate health. Men are becoming more educated on the long-term implications of prostate disease, such as incontinence or cancer, and are therefore more willing to invest in premium diagnostics, second opinions, and ongoing care regimens. These behavioral trends are gradually shifting the market from reactive treatment toward a more preventive, personalized, and patient-centric model.

The Growth in the Prostate Health Market Is Driven by Several Factors…

The growth in the prostate health market is driven by several factors related to demographic trends, evolving diagnostics, and shifting consumer behavior. Technological advancements in minimally invasive procedures, biomarker testing, and imaging modalities are allowing for earlier diagnosis and tailored interventions. From an end-use perspective, the rising patient volumes in urology clinics, specialty hospitals, and outpatient centers-especially in aging economies-are pushing demand for comprehensive screening and treatment services. Consumer preferences are also evolving, with increased acceptance of telehealth, personalized medicine, and at-home testing solutions influencing how care is delivered and consumed. Healthcare infrastructure expansion, particularly in emerging markets, is enabling broader access to prostate health services. Moreover, the pharmaceutical pipeline for prostate-related conditions is robust, with numerous clinical trials focused on novel hormonal therapies and combination regimens. The intersection of medical innovation, patient awareness, and systemic support is creating a fertile environment for the sustained growth of the prostate health market globally.

SCOPE OF STUDY:

The report analyzes the Prostate Health market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Disease Type (Prostatitis Disease Type, Benign Prostatic Hyperplasia Disease Type, Prostate Cancer Disease Type); Treatment (Chemotherapy Treatment, Hormone Therapy Treatment, Immunotherapy Treatment); Administration Route (Oral Route, Parenteral Route); Distribution Channel (Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel, Online Pharmacies Distribution Channel)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 37 Featured) -

• Abbott Laboratories
• Amgen Inc.
• Astellas Pharma Inc.
• AstraZeneca PLC
• Bayer AG
• Bristol-Myers Squibb Company
• Clovis Oncology, Inc.
• Eli Lilly and Company
• Endo Pharmaceuticals Inc.
• Ferring Pharmaceuticals Inc.
• GlaxoSmithKline plc
• Johnson & Johnson
• Merck & Co., Inc.
• Novartis AG
• Pfizer Inc.
• ProArc Medical Ltd.
• Quibim
• Sanofi
• Siemens Healthineers AG
• Veru Inc.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA <> CHINA <> MEXICO <> CANADA <> EU <> JAPAN <> INDIA <> 176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

COMPLIMENTARY PREVIEW

Contact your sales agent to request an online 300+ page complimentary preview of this research project. Our preview will present full stack sources, and validated domain expert data transcripts. Deep dive into our interactive data-driven online platform.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

• 1. MARKET OVERVIEW
  • Influencer Market Insights
  • World Market Trajectories
  • Impact of Covid-19 and a Looming Global Recession
  • Prostate Health - Global Key Competitors Percentage Market Share in 2025 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
• 2. FOCUS ON SELECT PLAYERS
• 3. MARKET TRENDS & DRIVERS
  • Rising Geriatric Population and Life Expectancy Drive Growth in Prostate Care Services
  • Increased Screening Awareness for Prostate Cancer Spurs Preventive Diagnosis Uptake
  • Technological Advancements in Imaging and Biopsy Tools Improve Diagnostic Accuracy
  • Minimally Invasive Surgery Techniques Propel Growth in Robotic-Assisted Treatments
  • Growing Prevalence of BPH (Benign Prostatic Hyperplasia) Generates Steady Medication Demand
  • Expansion of Telehealth Platforms Facilitates Access to Urologists and Treatment Continuity
  • Availability of Targeted Drug Therapies Improves Management of Advanced Prostate Conditions
  • Development of AI-Driven Diagnostics Tools Enhances Precision in Prostate Disease Detection
  • Public-Private Health Campaigns Promote Early Detection and Routine PSA Testing
  • Shift Toward Outpatient and Ambulatory Surgical Centers Expands Treatment Accessibility
  • Rising Male Health Awareness Initiatives Normalize Prostate Screenings Among Younger Demographics
  • Adoption of MRI-Ultrasound Fusion Systems Strengthens Clinical Decision-Making
  • Pharma R&D Pipelines Focus on Next-Generation Hormone Therapies for Prostate Cancer
  • Insurance Coverage Expansion in Key Markets Increases Treatment Affordability
  • Integration of Genomic Testing in Prostate Cancer Risk Assessment Creates Tailored Treatment Paths
• 4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World Prostate Health Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
  • TABLE 2: World Recent Past, Current & Future Analysis for Prostate Health by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 3: World Historic Review for Prostate Health by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 4: World 15-Year Perspective for Prostate Health by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
  • TABLE 5: World Recent Past, Current & Future Analysis for Prostatitis Disease Type by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 6: World Historic Review for Prostatitis Disease Type by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 7: World 15-Year Perspective for Prostatitis Disease Type by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 8: World Recent Past, Current & Future Analysis for Benign Prostatic Hyperplasia Disease Type by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 9: World Historic Review for Benign Prostatic Hyperplasia Disease Type by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 10: World 15-Year Perspective for Benign Prostatic Hyperplasia Disease Type by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 11: World Recent Past, Current & Future Analysis for Prostate Cancer Disease Type by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 12: World Historic Review for Prostate Cancer Disease Type by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 13: World 15-Year Perspective for Prostate Cancer Disease Type by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 14: World Recent Past, Current & Future Analysis for Retail Pharmacies Distribution Channel by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 15: World Historic Review for Retail Pharmacies Distribution Channel by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 16: World 15-Year Perspective for Retail Pharmacies Distribution Channel by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 17: World Recent Past, Current & Future Analysis for Online Pharmacies Distribution Channel by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 18: World Historic Review for Online Pharmacies Distribution Channel by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 19: World 15-Year Perspective for Online Pharmacies Distribution Channel by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 20: World Recent Past, Current & Future Analysis for Hospital Pharmacies Distribution Channel by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 21: World Historic Review for Hospital Pharmacies Distribution Channel by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 22: World 15-Year Perspective for Hospital Pharmacies Distribution Channel by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 23: World Recent Past, Current & Future Analysis for Chemotherapy Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 24: World Historic Review for Chemotherapy Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 25: World 15-Year Perspective for Chemotherapy Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 26: World Recent Past, Current & Future Analysis for Hormone Therapy Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 27: World Historic Review for Hormone Therapy Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 28: World 15-Year Perspective for Hormone Therapy Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 29: World Recent Past, Current & Future Analysis for Immunotherapy Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 30: World Historic Review for Immunotherapy Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 31: World 15-Year Perspective for Immunotherapy Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 32: World Recent Past, Current & Future Analysis for Oral Route by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 33: World Historic Review for Oral Route by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 34: World 15-Year Perspective for Oral Route by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 35: World Recent Past, Current & Future Analysis for Parenteral Route by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 36: World Historic Review for Parenteral Route by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 37: World 15-Year Perspective for Parenteral Route by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

• UNITED STATES
  • Prostate Health Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
  • TABLE 38: USA Recent Past, Current & Future Analysis for Prostate Health by Disease Type - Prostatitis Disease Type, Benign Prostatic Hyperplasia Disease Type and Prostate Cancer Disease Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 39: USA Historic Review for Prostate Health by Disease Type - Prostatitis Disease Type, Benign Prostatic Hyperplasia Disease Type and Prostate Cancer Disease Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 40: USA 15-Year Perspective for Prostate Health by Disease Type - Percentage Breakdown of Value Sales for Prostatitis Disease Type, Benign Prostatic Hyperplasia Disease Type and Prostate Cancer Disease Type for the Years 2015, 2025 & 2030
  • TABLE 41: USA Recent Past, Current & Future Analysis for Prostate Health by Distribution Channel - Retail Pharmacies Distribution Channel, Online Pharmacies Distribution Channel and Hospital Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 42: USA Historic Review for Prostate Health by Distribution Channel - Retail Pharmacies Distribution Channel, Online Pharmacies Distribution Channel and Hospital Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 43: USA 15-Year Perspective for Prostate Health by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies Distribution Channel, Online Pharmacies Distribution Channel and Hospital Pharmacies Distribution Channel for the Years 2015, 2025 & 2030
  • TABLE 44: USA Recent Past, Current & Future Analysis for Prostate Health by Treatment - Chemotherapy Treatment, Hormone Therapy Treatment and Immunotherapy Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 45: USA Historic Review for Prostate Health by Treatment - Chemotherapy Treatment, Hormone Therapy Treatment and Immunotherapy Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 46: USA 15-Year Perspective for Prostate Health by Treatment - Percentage Breakdown of Value Sales for Chemotherapy Treatment, Hormone Therapy Treatment and Immunotherapy Treatment for the Years 2015, 2025 & 2030
  • TABLE 47: USA Recent Past, Current & Future Analysis for Prostate Health by Administration Route - Oral Route and Parenteral Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 48: USA Historic Review for Prostate Health by Administration Route - Oral Route and Parenteral Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 49: USA 15-Year Perspective for Prostate Health by Administration Route - Percentage Breakdown of Value Sales for Oral Route and Parenteral Route for the Years 2015, 2025 & 2030
• CANADA
  • TABLE 50: Canada Recent Past, Current & Future Analysis for Prostate Health by Disease Type - Prostatitis Disease Type, Benign Prostatic Hyperplasia Disease Type and Prostate Cancer Disease Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 51: Canada Historic Review for Prostate Health by Disease Type - Prostatitis Disease Type, Benign Prostatic Hyperplasia Disease Type and Prostate Cancer Disease Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 52: Canada 15-Year Perspective for Prostate Health by Disease Type - Percentage Breakdown of Value Sales for Prostatitis Disease Type, Benign Prostatic Hyperplasia Disease Type and Prostate Cancer Disease Type for the Years 2015, 2025 & 2030
  • TABLE 53: Canada Recent Past, Current & Future Analysis for Prostate Health by Distribution Channel - Retail Pharmacies Distribution Channel, Online Pharmacies Distribution Channel and Hospital Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 54: Canada Historic Review for Prostate Health by Distribution Channel - Retail Pharmacies Distribution Channel, Online Pharmacies Distribution Channel and Hospital Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 55: Canada 15-Year Perspective for Prostate Health by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies Distribution Channel, Online Pharmacies Distribution Channel and Hospital Pharmacies Distribution Channel for the Years 2015, 2025 & 2030
  • TABLE 56: Canada Recent Past, Current & Future Analysis for Prostate Health by Treatment - Chemotherapy Treatment, Hormone Therapy Treatment and Immunotherapy Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 57: Canada Historic Review for Prostate Health by Treatment - Chemotherapy Treatment, Hormone Therapy Treatment and Immunotherapy Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 58: Canada 15-Year Perspective for Prostate Health by Treatment - Percentage Breakdown of Value Sales for Chemotherapy Treatment, Hormone Therapy Treatment and Immunotherapy Treatment for the Years 2015, 2025 & 2030
  • TABLE 59: Canada Recent Past, Current & Future Analysis for Prostate Health by Administration Route - Oral Route and Parenteral Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 60: Canada Historic Review for Prostate Health by Administration Route - Oral Route and Parenteral Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 61: Canada 15-Year Perspective for Prostate Health by Administration Route - Percentage Breakdown of Value Sales for Oral Route and Parenteral Route for the Years 2015, 2025 & 2030
• JAPAN
  • Prostate Health Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
  • TABLE 62: Japan Recent Past, Current & Future Analysis for Prostate Health by Disease Type - Prostatitis Disease Type, Benign Prostatic Hyperplasia Disease Type and Prostate Cancer Disease Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 63: Japan Historic Review for Prostate Health by Disease Type - Prostatitis Disease Type, Benign Prostatic Hyperplasia Disease Type and Prostate Cancer Disease Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 64: Japan 15-Year Perspective for Prostate Health by Disease Type - Percentage Breakdown of Value Sales for Prostatitis Disease Type, Benign Prostatic Hyperplasia Disease Type and Prostate Cancer Disease Type for the Years 2015, 2025 & 2030
  • TABLE 65: Japan Recent Past, Current & Future Analysis for Prostate Health by Distribution Channel - Retail Pharmacies Distribution Channel, Online Pharmacies Distribution Channel and Hospital Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 66: Japan Historic Review for Prostate Health by Distribution Channel - Retail Pharmacies Distribution Channel, Online Pharmacies Distribution Channel and Hospital Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 67: Japan 15-Year Perspective for Prostate Health by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies Distribution Channel, Online Pharmacies Distribution Channel and Hospital Pharmacies Distribution Channel for the Years 2015, 2025 & 2030
  • TABLE 68: Japan Recent Past, Current & Future Analysis for Prostate Health by Treatment - Chemotherapy Treatment, Hormone Therapy Treatment and Immunotherapy Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 69: Japan Historic Review for Prostate Health by Treatment - Chemotherapy Treatment, Hormone Therapy Treatment and Immunotherapy Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 70: Japan 15-Year Perspective for Prostate Health by Treatment - Percentage Breakdown of Value Sales for Chemotherapy Treatment, Hormone Therapy Treatment and Immunotherapy Treatment for the Years 2015, 2025 & 2030
  • TABLE 71: Japan Recent Past, Current & Future Analysis for Prostate Health by Administration Route - Oral Route and Parenteral Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 72: Japan Historic Review for Prostate Health by Administration Route - Oral Route and Parenteral Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 73: Japan 15-Year Perspective for Prostate Health by Administration Route - Percentage Breakdown of Value Sales for Oral Route and Parenteral Route for the Years 2015, 2025 & 2030
• CHINA
  • Prostate Health Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
  • TABLE 74: China Recent Past, Current & Future Analysis for Prostate Health by Disease Type - Prostatitis Disease Type, Benign Prostatic Hyperplasia Disease Type and Prostate Cancer Disease Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 75: China Historic Review for Prostate Health by Disease Type - Prostatitis Disease Type, Benign Prostatic Hyperplasia Disease Type and Prostate Cancer Disease Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 76: China 15-Year Perspective for Prostate Health by Disease Type - Percentage Breakdown of Value Sales for Prostatitis Disease Type, Benign Prostatic Hyperplasia Disease Type and Prostate Cancer Disease Type for the Years 2015, 2025 & 2030
  • TABLE 77: China Recent Past, Current & Future Analysis for Prostate Health by Distribution Channel - Retail Pharmacies Distribution Channel, Online Pharmacies Distribution Channel and Hospital Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 78: China Historic Review for Prostate Health by Distribution Channel - Retail Pharmacies Distribution Channel, Online Pharmacies Distribution Channel and Hospital Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 79: China 15-Year Perspective for Prostate Health by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies Distribution Channel, Online Pharmacies Distribution Channel and Hospital Pharmacies Distribution Channel for the Years 2015, 2025 & 2030
  • TABLE 80: China Recent Past, Current & Future Analysis for Prostate Health by Treatment - Chemotherapy Treatment, Hormone Therapy Treatment and Immunotherapy Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 81: China Historic Review for Prostate Health by Treatment - Chemotherapy Treatment, Hormone Therapy Treatment and Immunotherapy Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 82: China 15-Year Perspective for Prostate Health by Treatment - Percentage Breakdown of Value Sales for Chemotherapy Treatment, Hormone Therapy Treatment and Immunotherapy Treatment for the Years 2015, 2025 & 2030
  • TABLE 83: China Recent Past, Current & Future Analysis for Prostate Health by Administration Route - Oral Route and Parenteral Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 84: China Historic Review for Prostate Health by Administration Route - Oral Route and Parenteral Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 85: China 15-Year Perspective for Prostate Health by Administration Route - Percentage Breakdown of Value Sales for Oral Route and Parenteral Route for the Years 2015, 2025 & 2030
• EUROPE
  • Prostate Health Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
  • TABLE 86: Europe Recent Past, Current & Future Analysis for Prostate Health by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 87: Europe Historic Review for Prostate Health by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 88: Europe 15-Year Perspective for Prostate Health by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
  • TABLE 89: Europe Recent Past, Current & Future Analysis for Prostate Health by Disease Type - Prostatitis Disease Type, Benign Prostatic Hyperplasia Disease Type and Prostate Cancer Disease Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 90: Europe Historic Review for Prostate Health by Disease Type - Prostatitis Disease Type, Benign Prostatic Hyperplasia Disease Type and Prostate Cancer Disease Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 91: Europe 15-Year Perspective for Prostate Health by Disease Type - Percentage Breakdown of Value Sales for Prostatitis Disease Type, Benign Prostatic Hyperplasia Disease Type and Prostate Cancer Disease Type for the Years 2015, 2025 & 2030
  • TABLE 92: Europe Recent Past, Current & Future Analysis for Prostate Health by Distribution Channel - Retail Pharmacies Distribution Channel, Online Pharmacies Distribution Channel and Hospital Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 93: Europe Historic Review for Prostate Health by Distribution Channel - Retail Pharmacies Distribution Channel, Online Pharmacies Distribution Channel and Hospital Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 94: Europe 15-Year Perspective for Prostate Health by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies Distribution Channel, Online Pharmacies Distribution Channel and Hospital Pharmacies Distribution Channel for the Years 2015, 2025 & 2030
  • TABLE 95: Europe Recent Past, Current & Future Analysis for Prostate Health by Treatment - Chemotherapy Treatment, Hormone Therapy Treatment and Immunotherapy Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 96: Europe Historic Review for Prostate Health by Treatment - Chemotherapy Treatment, Hormone Therapy Treatment and Immunotherapy Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 97: Europe 15-Year Perspective for Prostate Health by Treatment - Percentage Breakdown of Value Sales for Chemotherapy Treatment, Hormone Therapy Treatment and Immunotherapy Treatment for the Years 2015, 2025 & 2030
  • TABLE 98: Europe Recent Past, Current & Future Analysis for Prostate Health by Administration Route - Oral Route and Parenteral Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 99: Europe Historic Review for Prostate Health by Administration Route - Oral Route and Parenteral Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 100: Europe 15-Year Perspective for Prostate Health by Administration Route - Percentage Breakdown of Value Sales for Oral Route and Parenteral Route for the Years 2015, 2025 & 2030
• FRANCE
  • Prostate Health Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
  • TABLE 101: France Recent Past, Current & Future Analysis for Prostate Health by Disease Type - Prostatitis Disease Type, Benign Prostatic Hyperplasia Disease Type and Prostate Cancer Disease Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 102: France Historic Review for Prostate Health by Disease Type - Prostatitis Disease Type, Benign Prostatic Hyperplasia Disease Type and Prostate Cancer Disease Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 103: France 15-Year Perspective for Prostate Health by Disease Type - Percentage Breakdown of Value Sales for Prostatitis Disease Type, Benign Prostatic Hyperplasia Disease Type and Prostate Cancer Disease Type for the Years 2015, 2025 & 2030
  • TABLE 104: France Recent Past, Current & Future Analysis for Prostate Health by Distribution Channel - Retail Pharmacies Distribution Channel, Online Pharmacies Distribution Channel and Hospital Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 105: France Historic Review for Prostate Health by Distribution Channel - Retail Pharmacies Distribution Channel, Online Pharmacies Distribution Channel and Hospital Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 106: France 15-Year Perspective for Prostate Health by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies Distribution Channel, Online Pharmacies Distribution Channel and Hospital Pharmacies Distribution Channel for the Years 2015, 2025 & 2030
  • TABLE 107: France Recent Past, Current & Future Analysis for Prostate Health by Treatment - Chemotherapy Treatment, Hormone Therapy Treatment and Immunotherapy Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 108: France Historic Review for Prostate Health by Treatment - Chemotherapy Treatment, Hormone Therapy Treatment and Immunotherapy Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 109: France 15-Year Perspective for Prostate Health by Treatment - Percentage Breakdown of Value Sales for Chemotherapy Treatment, Hormone Therapy Treatment and Immunotherapy Treatment for the Years 2015, 2025 & 2030
  • TABLE 110: France Recent Past, Current & Future Analysis for Prostate Health by Administration Route - Oral Route and Parenteral Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 111: France Historic Review for Prostate Health by Administration Route - Oral Route and Parenteral Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 112: France 15-Year Perspective for Prostate Health by Administration Route - Percentage Breakdown of Value Sales for Oral Route and Parenteral Route for the Years 2015, 2025 & 2030
• GERMANY
  • Prostate Health Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
  • TABLE 113: Germany Recent Past, Current & Future Analysis for Prostate Health by Disease Type - Prostatitis Disease Type, Benign Prostatic Hyperplasia Disease Type and Prostate Cancer Disease Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 114: Germany Historic Review for Prostate Health by Disease Type - Prostatitis Disease Type, Benign Prostatic Hyperplasia Disease Type and Prostate Cancer Disease Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 115: Germany 15-Year Perspective for Prostate Health by Disease Type - Percentage Breakdown of Value Sales for Prostatitis Disease Type, Benign Prostatic Hyperplasia Disease Type and Prostate Cancer Disease Type for the Years 2015, 2025 & 2030
  • TABLE 116: Germany Recent Past, Current & Future Analysis for Prostate Health by Distribution Channel - Retail Pharmacies Distribution Channel, Online Pharmacies Distribution Channel and Hospital Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 117: Germany Historic Review for Prostate Health by Distribution Channel - Retail Pharmacies Distribution Channel, Online Pharmacies Distribution Channel and Hospital Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 118: Germany 15-Year Perspective for Prostate Health by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies Distribution Channel, Online Pharmacies Distribution Channel and Hospital Pharmacies Distribution Channel for the Years 2015, 2025 & 2030
  • TABLE 119: Germany Recent Past, Current & Future Analysis for Prostate Health by Treatment - Chemotherapy Treatment, Hormone Therapy Treatment and Immunotherapy Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 120: Germany Historic Review for Prostate Health by Treatment - Chemotherapy Treatment, Hormone Therapy Treatment and Immunotherapy Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 121: Germany 15-Year Perspective for Prostate Health by Treatment - Percentage Breakdown of Value Sales for Chemotherapy Treatment, Hormone Therapy Treatment and Immunotherapy Treatment for the Years 2015, 2025 & 2030
  • TABLE 122: Germany Recent Past, Current & Future Analysis for Prostate Health by Administration Route - Oral Route and Parenteral Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 123: Germany Historic Review for Prostate Health by Administration Route - Oral Route and Parenteral Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 124: Germany 15-Year Perspective for Prostate Health by Administration Route - Percentage Breakdown of Value Sales for Oral Route and Parenteral Route for the Years 2015, 2025 & 2030
• ITALY
  • TABLE 125: Italy Recent Past, Current & Future Analysis for Prostate Health by Disease Type - Prostatitis Disease Type, Benign Prostatic Hyperplasia Disease Type and Prostate Cancer Disease Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 126: Italy Historic Review for Prostate Health by Disease Type - Prostatitis Disease Type, Benign Prostatic Hyperplasia Disease Type and Prostate Cancer Disease Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 127: Italy 15-Year Perspective for Prostate Health by Disease Type - Percentage Breakdown of Value Sales for Prostatitis Disease Type, Benign Prostatic Hyperplasia Disease Type and Prostate Cancer Disease Type for the Years 2015, 2025 & 2030
  • TABLE 128: Italy Recent Past, Current & Future Analysis for Prostate Health by Distribution Channel - Retail Pharmacies Distribution Channel, Online Pharmacies Distribution Channel and Hospital Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 129: Italy Historic Review for Prostate Health by Distribution Channel - Retail Pharmacies Distribution Channel, Online Pharmacies Distribution Channel and Hospital Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 130: Italy 15-Year Perspective for Prostate Health by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies Distribution Channel, Online Pharmacies Distribution Channel and Hospital Pharmacies Distribution Channel for the Years 2015, 2025 & 2030
  • TABLE 131: Italy Recent Past, Current & Future Analysis for Prostate Health by Treatment - Chemotherapy Treatment, Hormone Therapy Treatment and Immunotherapy Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 132: Italy Historic Review for Prostate Health by Treatment - Chemotherapy Treatment, Hormone Therapy Treatment and Immunotherapy Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 133: Italy 15-Year Perspective for Prostate Health by Treatment - Percentage Breakdown of Value Sales for Chemotherapy Treatment, Hormone Therapy Treatment and Immunotherapy Treatment for the Years 2015, 2025 & 2030
  • TABLE 134: Italy Recent Past, Current & Future Analysis for Prostate Health by Administration Route - Oral Route and Parenteral Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 135: Italy Historic Review for Prostate Health by Administration Route - Oral Route and Parenteral Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 136: Italy 15-Year Perspective for Prostate Health by Administration Route - Percentage Breakdown of Value Sales for Oral Route and Parenteral Route for the Years 2015, 2025 & 2030
• UNITED KINGDOM
  • Prostate Health Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
  • TABLE 137: UK Recent Past, Current & Future Analysis for Prostate Health by Disease Type - Prostatitis Disease Type, Benign Prostatic Hyperplasia Disease Type and Prostate Cancer Disease Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 138: UK Historic Review for Prostate Health by Disease Type - Prostatitis Disease Type, Benign Prostatic Hyperplasia Disease Type and Prostate Cancer Disease Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 139: UK 15-Year Perspective for Prostate Health by Disease Type - Percentage Breakdown of Value Sales for Prostatitis Disease Type, Benign Prostatic Hyperplasia Disease Type and Prostate Cancer Disease Type for the Years 2015, 2025 & 2030
  • TABLE 140: UK Recent Past, Current & Future Analysis for Prostate Health by Distribution Channel - Retail Pharmacies Distribution Channel, Online Pharmacies Distribution Channel and Hospital Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 141: UK Historic Review for Prostate Health by Distribution Channel - Retail Pharmacies Distribution Channel, Online Pharmacies Distribution Channel and Hospital Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 142: UK 15-Year Perspective for Prostate Health by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies Distribution Channel, Online Pharmacies Distribution Channel and Hospital Pharmacies Distribution Channel for the Years 2015, 2025 & 2030
  • TABLE 143: UK Recent Past, Current & Future Analysis for Prostate Health by Treatment - Chemotherapy Treatment, Hormone Therapy Treatment and Immunotherapy Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 144: UK Historic Review for Prostate Health by Treatment - Chemotherapy Treatment, Hormone Therapy Treatment and Immunotherapy Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 145: UK 15-Year Perspective for Prostate Health by Treatment - Percentage Breakdown of Value Sales for Chemotherapy Treatment, Hormone Therapy Treatment and Immunotherapy Treatment for the Years 2015, 2025 & 2030
  • TABLE 146: UK Recent Past, Current & Future Analysis for Prostate Health by Administration Route - Oral Route and Parenteral Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 147: UK Historic Review for Prostate Health by Administration Route - Oral Route and Parenteral Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 148: UK 15-Year Perspective for Prostate Health by Administration Route - Percentage Breakdown of Value Sales for Oral Route and Parenteral Route for the Years 2015, 2025 & 2030
• SPAIN
  • TABLE 149: Spain Recent Past, Current & Future Analysis for Prostate Health by Disease Type - Prostatitis Disease Type, Benign Prostatic Hyperplasia Disease Type and Prostate Cancer Disease Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 150: Spain Historic Review for Prostate Health by Disease Type - Prostatitis Disease Type, Benign Prostatic Hyperplasia Disease Type and Prostate Cancer Disease Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 151: Spain 15-Year Perspective for Prostate Health by Disease Type - Percentage Breakdown of Value Sales for Prostatitis Disease Type, Benign Prostatic Hyperplasia Disease Type and Prostate Cancer Disease Type for the Years 2015, 2025 & 2030
  • TABLE 152: Spain Recent Past, Current & Future Analysis for Prostate Health by Distribution Channel - Retail Pharmacies Distribution Channel, Online Pharmacies Distribution Channel and Hospital Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 153: Spain Historic Review for Prostate Health by Distribution Channel - Retail Pharmacies Distribution Channel, Online Pharmacies Distribution Channel and Hospital Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 154: Spain 15-Year Perspective for Prostate Health by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies Distribution Channel, Online Pharmacies Distribution Channel and Hospital Pharmacies Distribution Channel for the Years 2015, 2025 & 2030
  • TABLE 155: Spain Recent Past, Current & Future Analysis for Prostate Health by Treatment - Chemotherapy Treatment, Hormone Therapy Treatment and Immunotherapy Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 156: Spain Historic Review for Prostate Health by Treatment - Chemotherapy Treatment, Hormone Therapy Treatment and Immunotherapy Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 157: Spain 15-Year Perspective for Prostate Health by Treatment - Percentage Breakdown of Value Sales for Chemotherapy Treatment, Hormone Therapy Treatment and Immunotherapy Treatment for the Years 2015, 2025 & 2030
  • TABLE 158: Spain Recent Past, Current & Future Analysis for Prostate Health by Administration Route - Oral Route and Parenteral Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 159: Spain Historic Review for Prostate Health by Administration Route - Oral Route and Parenteral Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 160: Spain 15-Year Perspective for Prostate Health by Administration Route - Percentage Breakdown of Value Sales for Oral Route and Parenteral Route for the Years 2015, 2025 & 2030
• RUSSIA
  • TABLE 161: Russia Recent Past, Current & Future Analysis for Prostate Health by Disease Type - Prostatitis Disease Type, Benign Prostatic Hyperplasia Disease Type and Prostate Cancer Disease Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 162: Russia Historic Review for Prostate Health by Disease Type - Prostatitis Disease Type, Benign Prostatic Hyperplasia Disease Type and Prostate Cancer Disease Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 163: Russia 15-Year Perspective for Prostate Health by Disease Type - Percentage Breakdown of Value Sales for Prostatitis Disease Type, Benign Prostatic Hyperplasia Disease Type and Prostate Cancer Disease Type for the Years 2015, 2025 & 2030
  • TABLE 164: Russia Recent Past, Current & Future Analysis for Prostate Health by Distribution Channel - Retail Pharmacies Distribution Channel, Online Pharmacies Distribution Channel and Hospital Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 165: Russia Historic Review for Prostate Health by Distribution Channel - Retail Pharmacies Distribution Channel, Online Pharmacies Distribution Channel and Hospital Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 166: Russia 15-Year Perspective for Prostate Health by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies Distribution Channel, Online Pharmacies Distribution Channel and Hospital Pharmacies Distribution Channel for the Years 2015, 2025 & 2030
  • TABLE 167: Russia Recent Past, Current & Future Analysis for Prostate Health by Treatment - Chemotherapy Treatment, Hormone Therapy Treatment and Immunotherapy Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 168: Russia Historic Review for Prostate Health by Treatment - Chemotherapy Treatment, Hormone Therapy Treatment and Immunotherapy Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 169: Russia 15-Year Perspective for Prostate Health by Treatment - Percentage Breakdown of Value Sales for Chemotherapy Treatment, Hormone Therapy Treatment and Immunotherapy Treatment for the Years 2015, 2025 & 2030
  • TABLE 170: Russia Recent Past, Current & Future Analysis for Prostate Health by Administration Route - Oral Route and Parenteral Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 171: Russia Historic Review for Prostate Health by Administration Route - Oral Route and Parenteral Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 172: Russia 15-Year Perspective for Prostate Health by Administration Route - Percentage Breakdown of Value Sales for Oral Route and Parenteral Route for the Years 2015, 2025 & 2030
• REST OF EUROPE
  • TABLE 173: Rest of Europe Recent Past, Current & Future Analysis for Prostate Health by Disease Type - Prostatitis Disease Type, Benign Prostatic Hyperplasia Disease Type and Prostate Cancer Disease Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 174: Rest of Europe Historic Review for Prostate Health by Disease Type - Prostatitis Disease Type, Benign Prostatic Hyperplasia Disease Type and Prostate Cancer Disease Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 175: Rest of Europe 15-Year Perspective for Prostate Health by Disease Type - Percentage Breakdown of Value Sales for Prostatitis Disease Type, Benign Prostatic Hyperplasia Disease Type and Prostate Cancer Disease Type for the Years 2015, 2025 & 2030
  • TABLE 176: Rest of Europe Recent Past, Current & Future Analysis for Prostate Health by Distribution Channel - Retail Pharmacies Distribution Channel, Online Pharmacies Distribution Channel and Hospital Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 177: Rest of Europe Historic Review for Prostate Health by Distribution Channel - Retail Pharmacies Distribution Channel, Online Pharmacies Distribution Channel and Hospital Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 178: Rest of Europe 15-Year Perspective for Prostate Health by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies Distribution Channel, Online Pharmacies Distribution Channel and Hospital Pharmacies Distribution Channel for the Years 2015, 2025 & 2030
  • TABLE 179: Rest of Europe Recent Past, Current & Future Analysis for Prostate Health by Treatment - Chemotherapy Treatment, Hormone Therapy Treatment and Immunotherapy Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 180: Rest of Europe Historic Review for Prostate Health by Treatment - Chemotherapy Treatment, Hormone Therapy Treatment and Immunotherapy Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 181: Rest of Europe 15-Year Perspective for Prostate Health by Treatment - Percentage Breakdown of Value Sales for Chemotherapy Treatment, Hormone Therapy Treatment and Immunotherapy Treatment for the Years 2015, 2025 & 2030
  • TABLE 182: Rest of Europe Recent Past, Current & Future Analysis for Prostate Health by Administration Route - Oral Route and Parenteral Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 183: Rest of Europe Historic Review for Prostate Health by Administration Route - Oral Route and Parenteral Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 184: Rest of Europe 15-Year Perspective for Prostate Health by Administration Route - Percentage Breakdown of Value Sales for Oral Route and Parenteral Route for the Years 2015, 2025 & 2030
• ASIA-PACIFIC
  • Prostate Health Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
  • TABLE 185: Asia-Pacific Recent Past, Current & Future Analysis for Prostate Health by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 186: Asia-Pacific Historic Review for Prostate Health by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 187: Asia-Pacific 15-Year Perspective for Prostate Health by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
  • TABLE 188: Asia-Pacific Recent Past, Current & Future Analysis for Prostate Health by Disease Type - Prostatitis Disease Type, Benign Prostatic Hyperplasia Disease Type and Prostate Cancer Disease Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 189: Asia-Pacific Historic Review for Prostate Health by Disease Type - Prostatitis Disease Type, Benign Prostatic Hyperplasia Disease Type and Prostate Cancer Disease Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 190: Asia-Pacific 15-Year Perspective for Prostate Health by Disease Type - Percentage Breakdown of Value Sales for Prostatitis Disease Type, Benign Prostatic Hyperplasia Disease Type and Prostate Cancer Disease Type for the Years 2015, 2025 & 2030
  • TABLE 191: Asia-Pacific Recent Past, Current & Future Analysis for Prostate Health by Distribution Channel - Retail Pharmacies Distribution Channel, Online Pharmacies Distribution Channel and Hospital Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 192: Asia-Pacific Historic Review for Prostate Health by Distribution Channel - Retail Pharmacies Distribution Channel, Online Pharmacies Distribution Channel and Hospital Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 193: Asia-Pacific 15-Year Perspective for Prostate Health by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies Distribution Channel, Online Pharmacies Distribution Channel and Hospital Pharmacies Distribution Channel for the Years 2015, 2025 & 2030
  • TABLE 194: Asia-Pacific Recent Past, Current & Future Analysis for Prostate Health by Treatment - Chemotherapy Treatment, Hormone Therapy Treatment and Immunotherapy Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 195: Asia-Pacific Historic Review for Prostate Health by Treatment - Chemotherapy Treatment, Hormone Therapy Treatment and Immunotherapy Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 196: Asia-Pacific 15-Year Perspective for Prostate Health by Treatment - Percentage Breakdown of Value Sales for Chemotherapy Treatment, Hormone Therapy Treatment and Immunotherapy Treatment for the Years 2015, 2025 & 2030
  • TABLE 197: Asia-Pacific Recent Past, Current & Future Analysis for Prostate Health by Administration Route - Oral Route and Parenteral Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 198: Asia-Pacific Historic Review for Prostate Health by Administration Route - Oral Route and Parenteral Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 199: Asia-Pacific 15-Year Perspective for Prostate Health by Administration Route - Percentage Breakdown of Value Sales for Oral Route and Parenteral Route for the Years 2015, 2025 & 2030
• AUSTRALIA
  • Prostate Health Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
  • TABLE 200: Australia Recent Past, Current & Future Analysis for Prostate Health by Disease Type - Prostatitis Disease Type, Benign Prostatic Hyperplasia Disease Type and Prostate Cancer Disease Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 201: Australia Historic Review for Prostate Health by Disease Type - Prostatitis Disease Type, Benign Prostatic Hyperplasia Disease Type and Prostate Cancer Disease Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 202: Australia 15-Year Perspective for Prostate Health by Disease Type - Percentage Breakdown of Value Sales for Prostatitis Disease Type, Benign Prostatic Hyperplasia Disease Type and Prostate Cancer Disease Type for the Years 2015, 2025 & 2030
  • TABLE 203: Australia Recent Past, Current & Future Analysis for Prostate Health by Distribution Channel - Retail Pharmacies Distribution Channel, Online Pharmacies Distribution Channel and Hospital Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 204: Australia Historic Review for Prostate Health by Distribution Channel - Retail Pharmacies Distribution Channel, Online Pharmacies Distribution Channel and Hospital Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 205: Australia 15-Year Perspective for Prostate Health by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies Distribution Channel, Online Pharmacies Distribution Channel and Hospital Pharmacies Distribution Channel for the Years 2015, 2025 & 2030
  • TABLE 206: Australia Recent Past, Current & Future Analysis for Prostate Health by Treatment - Chemotherapy Treatment, Hormone Therapy Treatment and Immunotherapy Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 207: Australia Historic Review for Prostate Health by Treatment - Chemotherapy Treatment, Hormone Therapy Treatment and Immunotherapy Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 208: Australia 15-Year Perspective for Prostate Health by Treatment - Percentage Breakdown of Value Sales for Chemotherapy Treatment, Hormone Therapy Treatment and Immunotherapy Treatment for the Years 2015, 2025 & 2030
  • TABLE 209: Australia Recent Past, Current & Future Analysis for Prostate Health by Administration Route - Oral Route and Parenteral Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 210: Australia Historic Review for Prostate Health by Administration Route - Oral Route and Parenteral Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 211: Australia 15-Year Perspective for Prostate Health by Administration Route - Percentage Breakdown of Value Sales for Oral Route and Parenteral Route for the Years 2015, 2025 & 2030
• INDIA
  • Prostate Health Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
  • TABLE 212: India Recent Past, Current & Future Analysis for Prostate Health by Disease Type - Prostatitis Disease Type, Benign Prostatic Hyperplasia Disease Type and Prostate Cancer Disease Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 213: India Historic Review for Prostate Health by Disease Type - Prostatitis Disease Type, Benign Prostatic Hyperplasia Disease Type and Prostate Cancer Disease Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 214: India 15-Year Perspective for Prostate Health by Disease Type - Percentage Breakdown of Value Sales for Prostatitis Disease Type, Benign Prostatic Hyperplasia Disease Type and Prostate Cancer Disease Type for the Years 2015, 2025 & 2030
  • TABLE 215: India Recent Past, Current & Future Analysis for Prostate Health by Distribution Channel - Retail Pharmacies Distribution Channel, Online Pharmacies Distribution Channel and Hospital Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 216: India Historic Review for Prostate Health by Distribution Channel - Retail Pharmacies Distribution Channel, Online Pharmacies Distribution Channel and Hospital Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 217: India 15-Year Perspective for Prostate Health by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies Distribution Channel, Online Pharmacies Distribution Channel and Hospital Pharmacies Distribution Channel for the Years 2015, 2025 & 2030
  • TABLE 218: India Recent Past, Current & Future Analysis for Prostate Health by Treatment - Chemotherapy Treatment, Hormone Therapy Treatment and Immunotherapy Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 219: India Historic Review for Prostate Health by Treatment - Chemotherapy Treatment, Hormone Therapy Treatment and Immunotherapy Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 220: India 15-Year Perspective for Prostate Health by Treatment - Percentage Breakdown of Value Sales for Chemotherapy Treatment, Hormone Therapy Treatment and Immunotherapy Treatment for the Years 2015, 2025 & 2030
  • TABLE 221: India Recent Past, Current & Future Analysis for Prostate Health by Administration Route - Oral Route and Parenteral Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 222: India Historic Review for Prostate Health by Administration Route - Oral Route and Parenteral Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 223: India 15-Year Perspective for Prostate Health by Administration Route - Percentage Breakdown of Value Sales for Oral Route and Parenteral Route for the Years 2015, 2025 & 2030
• SOUTH KOREA
  • TABLE 224: South Korea Recent Past, Current & Future Analysis for Prostate Health by Disease Type - Prostatitis Disease Type, Benign Prostatic Hyperplasia Disease Type and Prostate Cancer Disease Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 225: South Korea Historic Review for Prostate Health by Disease Type - Prostatitis Disease Type, Benign Prostatic Hyperplasia Disease Type and Prostate Cancer Disease Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 226: South Korea 15-Year Perspective for Prostate Health by Disease Type - Percentage Breakdown of Value Sales for Prostatitis Disease Type, Benign Prostatic Hyperplasia Disease Type and Prostate Cancer Disease Type for the Years 2015, 2025 & 2030
  • TABLE 227: South Korea Recent Past, Current & Future Analysis for Prostate Health by Distribution Channel - Retail Pharmacies Distribution Channel, Online Pharmacies Distribution Channel and Hospital Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 228: South Korea Historic Review for Prostate Health by Distribution Channel - Retail Pharmacies Distribution Channel, Online Pharmacies Distribution Channel and Hospital Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 229: South Korea 15-Year Perspective for Prostate Health by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies Distribution Channel, Online Pharmacies Distribution Channel and Hospital Pharmacies Distribution Channel for the Years 2015, 2025 & 2030
  • TABLE 230: South Korea Recent Past, Current & Future Analysis for Prostate Health by Treatment - Chemotherapy Treatment, Hormone Therapy Treatment and Immunotherapy Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 231: South Korea Historic Review for Prostate Health by Treatment - Chemotherapy Treatment, Hormone Therapy Treatment and Immunotherapy Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 232: South Korea 15-Year Perspective for Prostate Health by Treatment - Percentage Breakdown of Value Sales for Chemotherapy Treatment, Hormone Therapy Treatment and Immunotherapy Treatment for the Years 2015, 2025 & 2030
  • TABLE 233: South Korea Recent Past, Current & Future Analysis for Prostate Health by Administration Route - Oral Route and Parenteral Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 234: South Korea Historic Review for Prostate Health by Administration Route - Oral Route and Parenteral Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 235: South Korea 15-Year Perspective for Prostate Health by Administration Route - Percentage Breakdown of Value Sales for Oral Route and Parenteral Route for the Years 2015, 2025 & 2030
• REST OF ASIA-PACIFIC
  • TABLE 236: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Prostate Health by Disease Type - Prostatitis Disease Type, Benign Prostatic Hyperplasia Disease Type and Prostate Cancer Disease Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 237: Rest of Asia-Pacific Historic Review for Prostate Health by Disease Type - Prostatitis Disease Type, Benign Prostatic Hyperplasia Disease Type and Prostate Cancer Disease Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 238: Rest of Asia-Pacific 15-Year Perspective for Prostate Health by Disease Type - Percentage Breakdown of Value Sales for Prostatitis Disease Type, Benign Prostatic Hyperplasia Disease Type and Prostate Cancer Disease Type for the Years 2015, 2025 & 2030
  • TABLE 239: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Prostate Health by Distribution Channel - Retail Pharmacies Distribution Channel, Online Pharmacies Distribution Channel and Hospital Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 240: Rest of Asia-Pacific Historic Review for Prostate Health by Distribution Channel - Retail Pharmacies Distribution Channel, Online Pharmacies Distribution Channel and Hospital Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 241: Rest of Asia-Pacific 15-Year Perspective for Prostate Health by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies Distribution Channel, Online Pharmacies Distribution Channel and Hospital Pharmacies Distribution Channel for the Years 2015, 2025 & 2030
  • TABLE 242: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Prostate Health by Treatment - Chemotherapy Treatment, Hormone Therapy Treatment and Immunotherapy Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 243: Rest of Asia-Pacific Historic Review for Prostate Health by Treatment - Chemotherapy Treatment, Hormone Therapy Treatment and Immunotherapy Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 244: Rest of Asia-Pacific 15-Year Perspective for Prostate Health by Treatment - Percentage Breakdown of Value Sales for Chemotherapy Treatment, Hormone Therapy Treatment and Immunotherapy Treatment for the Years 2015, 2025 & 2030
  • TABLE 245: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Prostate Health by Administration Route - Oral Route and Parenteral Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 246: Rest of Asia-Pacific Historic Review for Prostate Health by Administration Route - Oral Route and Parenteral Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 247: Rest of Asia-Pacific 15-Year Perspective for Prostate Health by Administration Route - Percentage Breakdown of Value Sales for Oral Route and Parenteral Route for the Years 2015, 2025 & 2030
• LATIN AMERICA
  • Prostate Health Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
  • TABLE 248: Latin America Recent Past, Current & Future Analysis for Prostate Health by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 249: Latin America Historic Review for Prostate Health by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 250: Latin America 15-Year Perspective for Prostate Health by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
  • TABLE 251: Latin America Recent Past, Current & Future Analysis for Prostate Health by Disease Type - Prostatitis Disease Type, Benign Prostatic Hyperplasia Disease Type and Prostate Cancer Disease Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 252: Latin America Historic Review for Prostate Health by Disease Type - Prostatitis Disease Type, Benign Prostatic Hyperplasia Disease Type and Prostate Cancer Disease Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 253: Latin America 15-Year Perspective for Prostate Health by Disease Type - Percentage Breakdown of Value Sales for Prostatitis Disease Type, Benign Prostatic Hyperplasia Disease Type and Prostate Cancer Disease Type for the Years 2015, 2025 & 2030
  • TABLE 254: Latin America Recent Past, Current & Future Analysis for Prostate Health by Distribution Channel - Retail Pharmacies Distribution Channel, Online Pharmacies Distribution Channel and Hospital Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 255: Latin America Historic Review for Prostate Health by Distribution Channel - Retail Pharmacies Distribution Channel, Online Pharmacies Distribution Channel and Hospital Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 256: Latin America 15-Year Perspective for Prostate Health by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies Distribution Channel, Online Pharmacies Distribution Channel and Hospital Pharmacies Distribution Channel for the Years 2015, 2025 & 2030
  • TABLE 257: Latin America Recent Past, Current & Future Analysis for Prostate Health by Treatment - Chemotherapy Treatment, Hormone Therapy Treatment and Immunotherapy Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 258: Latin America Historic Review for Prostate Health by Treatment - Chemotherapy Treatment, Hormone Therapy Treatment and Immunotherapy Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 259: Latin America 15-Year Perspective for Prostate Health by Treatment - Percentage Breakdown of Value Sales for Chemotherapy Treatment, Hormone Therapy Treatment and Immunotherapy Treatment for the Years 2015, 2025 & 2030
  • TABLE 260: Latin America Recent Past, Current & Future Analysis for Prostate Health by Administration Route - Oral Route and Parenteral Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 261: Latin America Historic Review for Prostate Health by Administration Route - Oral Route and Parenteral Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 262: Latin America 15-Year Perspective for Prostate Health by Administration Route - Percentage Breakdown of Value Sales for Oral Route and Parenteral Route for the Years 2015, 2025 & 2030
• ARGENTINA
  • TABLE 263: Argentina Recent Past, Current & Future Analysis for Prostate Health by Disease Type - Prostatitis Disease Type, Benign Prostatic Hyperplasia Disease Type and Prostate Cancer Disease Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 264: Argentina Historic Review for Prostate Health by Disease Type - Prostatitis Disease Type, Benign Prostatic Hyperplasia Disease Type and Prostate Cancer Disease Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 265: Argentina 15-Year Perspective for Prostate Health by Disease Type - Percentage Breakdown of Value Sales for Prostatitis Disease Type, Benign Prostatic Hyperplasia Disease Type and Prostate Cancer Disease Type for the Years 2015, 2025 & 2030
  • TABLE 266: Argentina Recent Past, Current & Future Analysis for Prostate Health by Distribution Channel - Retail Pharmacies Distribution Channel, Online Pharmacies Distribution Channel and Hospital Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 267: Argentina Historic Review for Prostate Health by Distribution Channel - Retail Pharmacies Distribution Channel, Online Pharmacies Distribution Channel and Hospital Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 268: Argentina 15-Year Perspective for Prostate Health by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies Distribution Channel, Online Pharmacies Distribution Channel and Hospital Pharmacies Distribution Channel for the Years 2015, 2025 & 2030
  • TABLE 269: Argentina Recent Past, Current & Future Analysis for Prostate Health by Treatment - Chemotherapy Treatment, Hormone Therapy Treatment and Immunotherapy Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 270: Argentina Historic Review for Prostate Health by Treatment - Chemotherapy Treatment, Hormone Therapy Treatment and Immunotherapy Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 271: Argentina 15-Year Perspective for Prostate Health by Treatment - Percentage Breakdown of Value Sales for Chemotherapy Treatment, Hormone Therapy Treatment and Immunotherapy Treatment for the Years 2015, 2025 & 2030
  • TABLE 272: Argentina Recent Past, Current & Future Analysis for Prostate Health by Administration Route - Oral Route and Parenteral Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 273: Argentina Historic Review for Prostate Health by Administration Route - Oral Route and Parenteral Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 274: Argentina 15-Year Perspective for Prostate Health by Administration Route - Percentage Breakdown of Value Sales for Oral Route and Parenteral Route for the Years 2015, 2025 & 2030
• BRAZIL
  • TABLE 275: Brazil Recent Past, Current & Future Analysis for Prostate Health by Disease Type - Prostatitis Disease Type, Benign Prostatic Hyperplasia Disease Type and Prostate Cancer Disease Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 276: Brazil Historic Review for Prostate Health by Disease Type - Prostatitis Disease Type, Benign Prostatic Hyperplasia Disease Type and Prostate Cancer Disease Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 277: Brazil 15-Year Perspective for Prostate Health by Disease Type - Percentage Breakdown of Value Sales for Prostatitis Disease Type, Benign Prostatic Hyperplasia Disease Type and Prostate Cancer Disease Type for the Years 2015, 2025 & 2030
  • TABLE 278: Brazil Recent Past, Current & Future Analysis for Prostate Health by Distribution Channel - Retail Pharmacies Distribution Channel, Online Pharmacies Distribution Channel and Hospital Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 279: Brazil Historic Review for Prostate Health by Distribution Channel - Retail Pharmacies Distribution Channel, Online Pharmacies Distribution Channel and Hospital Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 280: Brazil 15-Year Perspective for Prostate Health by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies Distribution Channel, Online Pharmacies Distribution Channel and Hospital Pharmacies Distribution Channel for the Years 2015, 2025 & 2030
  • TABLE 281: Brazil Recent Past, Current & Future Analysis for Prostate Health by Treatment - Chemotherapy Treatment, Hormone Therapy Treatment and Immunotherapy Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 282: Brazil Historic Review for Prostate Health by Treatment - Chemotherapy Treatment, Hormone Therapy Treatment and Immunotherapy Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 283: Brazil 15-Year Perspective for Prostate Health by Treatment - Percentage Breakdown of Value Sales for Chemotherapy Treatment, Hormone Therapy Treatment and Immunotherapy Treatment for the Years 2015, 2025 & 2030
  • TABLE 284: Brazil Recent Past, Current & Future Analysis for Prostate Health by Administration Route - Oral Route and Parenteral Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 285: Brazil Historic Review for Prostate Health by Administration Route - Oral Route and Parenteral Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 286: Brazil 15-Year Perspective for Prostate Health by Administration Route - Percentage Breakdown of Value Sales for Oral Route and Parenteral Route for the Years 2015, 2025 & 2030
• MEXICO
  • TABLE 287: Mexico Recent Past, Current & Future Analysis for Prostate Health by Disease Type - Prostatitis Disease Type, Benign Prostatic Hyperplasia Disease Type and Prostate Cancer Disease Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 288: Mexico Historic Review for Prostate Health by Disease Type - Prostatitis Disease Type, Benign Prostatic Hyperplasia Disease Type and Prostate Cancer Disease Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 289: Mexico 15-Year Perspective for Prostate Health by Disease Type - Percentage Breakdown of Value Sales for Prostatitis Disease Type, Benign Prostatic Hyperplasia Disease Type and Prostate Cancer Disease Type for the Years 2015, 2025 & 2030
  • TABLE 290: Mexico Recent Past, Current & Future Analysis for Prostate Health by Distribution Channel - Retail Pharmacies Distribution Channel, Online Pharmacies Distribution Channel and Hospital Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 291: Mexico Historic Review for Prostate Health by Distribution Channel - Retail Pharmacies Distribution Channel, Online Pharmacies Distribution Channel and Hospital Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 292: Mexico 15-Year Perspective for Prostate Health by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies Distribution Channel, Online Pharmacies Distribution Channel and Hospital Pharmacies Distribution Channel for the Years 2015, 2025 & 2030
  • TABLE 293: Mexico Recent Past, Current & Future Analysis for Prostate Health by Treatment - Chemotherapy Treatment, Hormone Therapy Treatment and Immunotherapy Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 294: Mexico Historic Review for Prostate Health by Treatment - Chemotherapy Treatment, Hormone Therapy Treatment and Immunotherapy Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 295: Mexico 15-Year Perspective for Prostate Health by Treatment - Percentage Breakdown of Value Sales for Chemotherapy Treatment, Hormone Therapy Treatment and Immunotherapy Treatment for the Years 2015, 2025 & 2030
  • TABLE 296: Mexico Recent Past, Current & Future Analysis for Prostate Health by Administration Route - Oral Route and Parenteral Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 297: Mexico Historic Review for Prostate Health by Administration Route - Oral Route and Parenteral Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 298: Mexico 15-Year Perspective for Prostate Health by Administration Route - Percentage Breakdown of Value Sales for Oral Route and Parenteral Route for the Years 2015, 2025 & 2030
• REST OF LATIN AMERICA
  • TABLE 299: Rest of Latin America Recent Past, Current & Future Analysis for Prostate Health by Disease Type - Prostatitis Disease Type, Benign Prostatic Hyperplasia Disease Type and Prostate Cancer Disease Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 300: Rest of Latin America Historic Review for Prostate Health by Disease Type - Prostatitis Disease Type, Benign Prostatic Hyperplasia Disease Type and Prostate Cancer Disease Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 301: Rest of Latin America 15-Year Perspective for Prostate Health by Disease Type - Percentage Breakdown of Value Sales for Prostatitis Disease Type, Benign Prostatic Hyperplasia Disease Type and Prostate Cancer Disease Type for the Years 2015, 2025 & 2030
  • TABLE 302: Rest of Latin America Recent Past, Current & Future Analysis for Prostate Health by Distribution Channel - Retail Pharmacies Distribution Channel, Online Pharmacies Distribution Channel and Hospital Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 303: Rest of Latin America Historic Review for Prostate Health by Distribution Channel - Retail Pharmacies Distribution Channel, Online Pharmacies Distribution Channel and Hospital Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 304: Rest of Latin America 15-Year Perspective for Prostate Health by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies Distribution Channel, Online Pharmacies Distribution Channel and Hospital Pharmacies Distribution Channel for the Years 2015, 2025 & 2030
  • TABLE 305: Rest of Latin America Recent Past, Current & Future Analysis for Prostate Health by Treatment - Chemotherapy Treatment, Hormone Therapy Treatment and Immunotherapy Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 306: Rest of Latin America Historic Review for Prostate Health by Treatment - Chemotherapy Treatment, Hormone Therapy Treatment and Immunotherapy Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 307: Rest of Latin America 15-Year Perspective for Prostate Health by Treatment - Percentage Breakdown of Value Sales for Chemotherapy Treatment, Hormone Therapy Treatment and Immunotherapy Treatment for the Years 2015, 2025 & 2030
  • TABLE 308: Rest of Latin America Recent Past, Current & Future Analysis for Prostate Health by Administration Route - Oral Route and Parenteral Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 309: Rest of Latin America Historic Review for Prostate Health by Administration Route - Oral Route and Parenteral Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 310: Rest of Latin America 15-Year Perspective for Prostate Health by Administration Route - Percentage Breakdown of Value Sales for Oral Route and Parenteral Route for the Years 2015, 2025 & 2030
• MIDDLE EAST
  • Prostate Health Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
  • TABLE 311: Middle East Recent Past, Current & Future Analysis for Prostate Health by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 312: Middle East Historic Review for Prostate Health by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 313: Middle East 15-Year Perspective for Prostate Health by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
  • TABLE 314: Middle East Recent Past, Current & Future Analysis for Prostate Health by Disease Type - Prostatitis Disease Type, Benign Prostatic Hyperplasia Disease Type and Prostate Cancer Disease Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 315: Middle East Historic Review for Prostate Health by Disease Type - Prostatitis Disease Type, Benign Prostatic Hyperplasia Disease Type and Prostate Cancer Disease Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 316: Middle East 15-Year Perspective for Prostate Health by Disease Type - Percentage Breakdown of Value Sales for Prostatitis Disease Type, Benign Prostatic Hyperplasia Disease Type and Prostate Cancer Disease Type for the Years 2015, 2025 & 2030
  • TABLE 317: Middle East Recent Past, Current & Future Analysis for Prostate Health by Distribution Channel - Retail Pharmacies Distribution Channel, Online Pharmacies Distribution Channel and Hospital Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 318: Middle East Historic Review for Prostate Health by Distribution Channel - Retail Pharmacies Distribution Channel, Online Pharmacies Distribution Channel and Hospital Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 319: Middle East 15-Year Perspective for Prostate Health by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies Distribution Channel, Online Pharmacies Distribution Channel and Hospital Pharmacies Distribution Channel for the Years 2015, 2025 & 2030
  • TABLE 320: Middle East Recent Past, Current & Future Analysis for Prostate Health by Treatment - Chemotherapy Treatment, Hormone Therapy Treatment and Immunotherapy Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 321: Middle East Historic Review for Prostate Health by Treatment - Chemotherapy Treatment, Hormone Therapy Treatment and Immunotherapy Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 322: Middle East 15-Year Perspective for Prostate Health by Treatment - Percentage Breakdown of Value Sales for Chemotherapy Treatment, Hormone Therapy Treatment and Immunotherapy Treatment for the Years 2015, 2025 & 2030
  • TABLE 323: Middle East Recent Past, Current & Future Analysis for Prostate Health by Administration Route - Oral Route and Parenteral Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 324: Middle East Historic Review for Prostate Health by Administration Route - Oral Route and Parenteral Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 325: Middle East 15-Year Perspective for Prostate Health by Administration Route - Percentage Breakdown of Value Sales for Oral Route and Parenteral Route for the Years 2015, 2025 & 2030
• IRAN
  • TABLE 326: Iran Recent Past, Current & Future Analysis for Prostate Health by Disease Type - Prostatitis Disease Type, Benign Prostatic Hyperplasia Disease Type and Prostate Cancer Disease Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 327: Iran Historic Review for Prostate Health by Disease Type - Prostatitis Disease Type, Benign Prostatic Hyperplasia Disease Type and Prostate Cancer Disease Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 328: Iran 15-Year Perspective for Prostate Health by Disease Type - Percentage Breakdown of Value Sales for Prostatitis Disease Type, Benign Prostatic Hyperplasia Disease Type and Prostate Cancer Disease Type for the Years 2015, 2025 & 2030
  • TABLE 329: Iran Recent Past, Current & Future Analysis for Prostate Health by Distribution Channel - Retail Pharmacies Distribution Channel, Online Pharmacies Distribution Channel and Hospital Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 330: Iran Historic Review for Prostate Health by Distribution Channel - Retail Pharmacies Distribution Channel, Online Pharmacies Distribution Channel and Hospital Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 331: Iran 15-Year Perspective for Prostate Health by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies Distribution Channel, Online Pharmacies Distribution Channel and Hospital Pharmacies Distribution Channel for the Years 2015, 2025 & 2030
  • TABLE 332: Iran Recent Past, Current & Future Analysis for Prostate Health by Treatment - Chemotherapy Treatment, Hormone Therapy Treatment and Immunotherapy Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 333: Iran Historic Review for Prostate Health by Treatment - Chemotherapy Treatment, Hormone Therapy Treatment and Immunotherapy Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 334: Iran 15-Year Perspective for Prostate Health by Treatment - Percentage Breakdown of Value Sales for Chemotherapy Treatment, Hormone Therapy Treatment and Immunotherapy Treatment for the Years 2015, 2025 & 2030
  • TABLE 335: Iran Recent Past, Current & Future Analysis for Prostate Health by Administration Route - Oral Route and Parenteral Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 336: Iran Historic Review for Prostate Health by Administration Route - Oral Route and Parenteral Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 337: Iran 15-Year Perspective for Prostate Health by Administration Route - Percentage Breakdown of Value Sales for Oral Route and Parenteral Route for the Years 2015, 2025 & 2030
• ISRAEL
  • TABLE 338: Israel Recent Past, Current & Future Analysis for Prostate Health by Disease Type - Prostatitis Disease Type, Benign Prostatic Hyperplasia Disease Type and Prostate Cancer Disease Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 339: Israel Historic Review for Prostate Health by Disease Type - Prostatitis Disease Type, Benign Prostatic Hyperplasia Disease Type and Prostate Cancer Disease Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 340: Israel 15-Year Perspective for Prostate Health by Disease Type - Percentage Breakdown of Value Sales for Prostatitis Disease Type, Benign Prostatic Hyperplasia Disease Type and Prostate Cancer Disease Type for the Years 2015, 2025 & 2030
  • TABLE 341: Israel Recent Past, Current & Future Analysis for Prostate Health by Distribution Channel - Retail Pharmacies Distribution Channel, Online Pharmacies Distribution Channel and Hospital Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 342: Israel Historic Review for Prostate Health by Distribution Channel - Retail Pharmacies Distribution Channel, Online Pharmacies Distribution Channel and Hospital Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 343: Israel 15-Year Perspective for Prostate Health by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies Distribution Channel, Online Pharmacies Distribution Channel and Hospital Pharmacies Distribution Channel for the Years 2015, 2025 & 2030
  • TABLE 344: Israel Recent Past, Current & Future Analysis for Prostate Health by Treatment - Chemotherapy Treatment, Hormone Therapy Treatment and Immunotherapy Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 345: Israel Historic Review for Prostate Health by Treatment - Chemotherapy Treatment, Hormone Therapy Treatment and Immunotherapy Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 346: Israel 15-Year Perspective for Prostate Health by Treatment - Percentage Breakdown of Value Sales for Chemotherapy Treatment, Hormone Therapy Treatment and Immunotherapy Treatment for the Years 2015, 2025 & 2030
  • TABLE 347: Israel Recent Past, Current & Future Analysis for Prostate Health by Administration Route - Oral Route and Parenteral Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 348: Israel Historic Review for Prostate Health by Administration Route - Oral Route and Parenteral Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 349: Israel 15-Year Perspective for Prostate Health by Administration Route - Percentage Breakdown of Value Sales for Oral Route and Parenteral Route for the Years 2015, 2025 & 2030
• SAUDI ARABIA
  • TABLE 350: Saudi Arabia Recent Past, Current & Future Analysis for Prostate Health by Disease Type - Prostatitis Disease Type, Benign Prostatic Hyperplasia Disease Type and Prostate Cancer Disease Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 351: Saudi Arabia Historic Review for Prostate Health by Disease Type - Prostatitis Disease Type, Benign Prostatic Hyperplasia Disease Type and Prostate Cancer Disease Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 352: Saudi Arabia 15-Year Perspective for Prostate Health by Disease Type - Percentage Breakdown of Value Sales for Prostatitis Disease Type, Benign Prostatic Hyperplasia Disease Type and Prostate Cancer Disease Type for the Years 2015, 2025 & 2030
  • TABLE 353: Saudi Arabia Recent Past, Current & Future Analysis for Prostate Health by Distribution Channel - Retail Pharmacies Distribution Channel, Online Pharmacies Distribution Channel and Hospital Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 354: Saudi Arabia Historic Review for Prostate Health by Distribution Channel - Retail Pharmacies Distribution Channel, Online Pharmacies Distribution Channel and Hospital Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 355: Saudi Arabia 15-Year Perspective for Prostate Health by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies Distribution Channel, Online Pharmacies Distribution Channel and Hospital Pharmacies Distribution Channel for the Years 2015, 2025 & 2030
  • TABLE 356: Saudi Arabia Recent Past, Current & Future Analysis for Prostate Health by Treatment - Chemotherapy Treatment, Hormone Therapy Treatment and Immunotherapy Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 357: Saudi Arabia Historic Review for Prostate Health by Treatment - Chemotherapy Treatment, Hormone Therapy Treatment and Immunotherapy Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 358: Saudi Arabia 15-Year Perspective for Prostate Health by Treatment - Percentage Breakdown of Value Sales for Chemotherapy Treatment, Hormone Therapy Treatment and Immunotherapy Treatment for the Years 2015, 2025 & 2030
  • TABLE 359: Saudi Arabia Recent Past, Current & Future Analysis for Prostate Health by Administration Route - Oral Route and Parenteral Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 360: Saudi Arabia Historic Review for Prostate Health by Administration Route - Oral Route and Parenteral Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 361: Saudi Arabia 15-Year Perspective for Prostate Health by Administration Route - Percentage Breakdown of Value Sales for Oral Route and Parenteral Route for the Years 2015, 2025 & 2030
• UNITED ARAB EMIRATES
  • TABLE 362: UAE Recent Past, Current & Future Analysis for Prostate Health by Disease Type - Prostatitis Disease Type, Benign Prostatic Hyperplasia Disease Type and Prostate Cancer Disease Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 363: UAE Historic Review for Prostate Health by Disease Type - Prostatitis Disease Type, Benign Prostatic Hyperplasia Disease Type and Prostate Cancer Disease Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 364: UAE 15-Year Perspective for Prostate Health by Disease Type - Percentage Breakdown of Value Sales for Prostatitis Disease Type, Benign Prostatic Hyperplasia Disease Type and Prostate Cancer Disease Type for the Years 2015, 2025 & 2030
  • TABLE 365: UAE Recent Past, Current & Future Analysis for Prostate Health by Distribution Channel - Retail Pharmacies Distribution Channel, Online Pharmacies Distribution Channel and Hospital Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 366: UAE Historic Review for Prostate Health by Distribution Channel - Retail Pharmacies Distribution Channel, Online Pharmacies Distribution Channel and Hospital Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 367: UAE 15-Year Perspective for Prostate Health by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies Distribution Channel, Online Pharmacies Distribution Channel and Hospital Pharmacies Distribution Channel for the Years 2015, 2025 & 2030
  • TABLE 368: UAE Recent Past, Current & Future Analysis for Prostate Health by Treatment - Chemotherapy Treatment, Hormone Therapy Treatment and Immunotherapy Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 369: UAE Historic Review for Prostate Health by Treatment - Chemotherapy Treatment, Hormone Therapy Treatment and Immunotherapy Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 370: UAE 15-Year Perspective for Prostate Health by Treatment - Percentage Breakdown of Value Sales for Chemotherapy Treatment, Hormone Therapy Treatment and Immunotherapy Treatment for the Years 2015, 2025 & 2030
  • TABLE 371: UAE Recent Past, Current & Future Analysis for Prostate Health by Administration Route - Oral Route and Parenteral Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 372: UAE Historic Review for Prostate Health by Administration Route - Oral Route and Parenteral Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 373: UAE 15-Year Perspective for Prostate Health by Administration Route - Percentage Breakdown of Value Sales for Oral Route and Parenteral Route for the Years 2015, 2025 & 2030
• REST OF MIDDLE EAST
  • TABLE 374: Rest of Middle East Recent Past, Current & Future Analysis for Prostate Health by Disease Type - Prostatitis Disease Type, Benign Prostatic Hyperplasia Disease Type and Prostate Cancer Disease Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 375: Rest of Middle East Historic Review for Prostate Health by Disease Type - Prostatitis Disease Type, Benign Prostatic Hyperplasia Disease Type and Prostate Cancer Disease Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 376: Rest of Middle East 15-Year Perspective for Prostate Health by Disease Type - Percentage Breakdown of Value Sales for Prostatitis Disease Type, Benign Prostatic Hyperplasia Disease Type and Prostate Cancer Disease Type for the Years 2015, 2025 & 2030
  • TABLE 377: Rest of Middle East Recent Past, Current & Future Analysis for Prostate Health by Distribution Channel - Retail Pharmacies Distribution Channel, Online Pharmacies Distribution Channel and Hospital Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 378: Rest of Middle East Historic Review for Prostate Health by Distribution Channel - Retail Pharmacies Distribution Channel, Online Pharmacies Distribution Channel and Hospital Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 379: Rest of Middle East 15-Year Perspective for Prostate Health by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies Distribution Channel, Online Pharmacies Distribution Channel and Hospital Pharmacies Distribution Channel for the Years 2015, 2025 & 2030
  • TABLE 380: Rest of Middle East Recent Past, Current & Future Analysis for Prostate Health by Treatment - Chemotherapy Treatment, Hormone Therapy Treatment and Immunotherapy Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 381: Rest of Middle East Historic Review for Prostate Health by Treatment - Chemotherapy Treatment, Hormone Therapy Treatment and Immunotherapy Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 382: Rest of Middle East 15-Year Perspective for Prostate Health by Treatment - Percentage Breakdown of Value Sales for Chemotherapy Treatment, Hormone Therapy Treatment and Immunotherapy Treatment for the Years 2015, 2025 & 2030
  • TABLE 383: Rest of Middle East Recent Past, Current & Future Analysis for Prostate Health by Administration Route - Oral Route and Parenteral Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 384: Rest of Middle East Historic Review for Prostate Health by Administration Route - Oral Route and Parenteral Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 385: Rest of Middle East 15-Year Perspective for Prostate Health by Administration Route - Percentage Breakdown of Value Sales for Oral Route and Parenteral Route for the Years 2015, 2025 & 2030
• AFRICA
  • Prostate Health Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
  • TABLE 386: Africa Recent Past, Current & Future Analysis for Prostate Health by Disease Type - Prostatitis Disease Type, Benign Prostatic Hyperplasia Disease Type and Prostate Cancer Disease Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 387: Africa Historic Review for Prostate Health by Disease Type - Prostatitis Disease Type, Benign Prostatic Hyperplasia Disease Type and Prostate Cancer Disease Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 388: Africa 15-Year Perspective for Prostate Health by Disease Type - Percentage Breakdown of Value Sales for Prostatitis Disease Type, Benign Prostatic Hyperplasia Disease Type and Prostate Cancer Disease Type for the Years 2015, 2025 & 2030
  • TABLE 389: Africa Recent Past, Current & Future Analysis for Prostate Health by Distribution Channel - Retail Pharmacies Distribution Channel, Online Pharmacies Distribution Channel and Hospital Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 390: Africa Historic Review for Prostate Health by Distribution Channel - Retail Pharmacies Distribution Channel, Online Pharmacies Distribution Channel and Hospital Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 391: Africa 15-Year Perspective for Prostate Health by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies Distribution Channel, Online Pharmacies Distribution Channel and Hospital Pharmacies Distribution Channel for the Years 2015, 2025 & 2030
  • TABLE 392: Africa Recent Past, Current & Future Analysis for Prostate Health by Treatment - Chemotherapy Treatment, Hormone Therapy Treatment and Immunotherapy Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 393: Africa Historic Review for Prostate Health by Treatment - Chemotherapy Treatment, Hormone Therapy Treatment and Immunotherapy Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 394: Africa 15-Year Perspective for Prostate Health by Treatment - Percentage Breakdown of Value Sales for Chemotherapy Treatment, Hormone Therapy Treatment and Immunotherapy Treatment for the Years 2015, 2025 & 2030
  • TABLE 395: Africa Recent Past, Current & Future Analysis for Prostate Health by Administration Route - Oral Route and Parenteral Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 396: Africa Historic Review for Prostate Health by Administration Route - Oral Route and Parenteral Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 397: Africa 15-Year Perspective for Prostate Health by Administration Route - Percentage Breakdown of Value Sales for Oral Route and Parenteral Route for the Years 2015, 2025 & 2030

IV. COMPETITION